Sign Up to like & get
recommendations!
0
Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16088
Abstract: Ibrutinib is associated with response rate of 90% and median progression‐free survival (PFS) in excess of 5 years in Waldenström macroglobulinaemia (WM) patients. CXCR4 mutations are detected in 30–40% of patients with WM and associate…
read more here.
Keywords:
pfs;
response;
cxcr4 mutations;
waldenstr macroglobulinaemia ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-23-3939
Abstract: Abstract Purpose: This study aims to explore the incidence and clinical features of MYD88 and CXCR4 mutations in patients with Waldenström macroglobulinemia (WM) and determine the optimal method for routine clinical practice. Additionally, we seek…
read more here.
Keywords:
myd88 cxcr4;
cxcr4;
waldenstr macroglobulinemia;
group ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202324
Abstract: Introduction Waldenström macroglobulinemia (WM) is a rare B-cell lymphoma characterized by prevalent MYD88 and CXCR4 mutations. Despite their importance, standardized approaches for detecting these mutations are limited. Additionally, few studies have integrated these gene mutations…
read more here.
Keywords:
myd88 cxcr4;
group;
cxcr4 mutations;
mutation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1406532
Abstract: Heterozygous autosomal dominant mutations in the CXCR4 gene cause WHIM syndrome, a severe combined immunodeficiency disorder. The mutations primarily affect the C-terminal region of the CXCR4 chemokine receptor, specifically several potential phosphorylation sites critical for…
read more here.
Keywords:
mutations whim;
cxcr4;
nature cxcr4;
whim syndrome ... See more keywords